PMID- 22199331
OWN - NLM
STAT- MEDLINE
DCOM- 20120222
LR  - 20151119
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 31
IP  - 12
DP  - 2011 Dec
TI  - Prospective study evaluating the plasma concentrations of twenty-six cytokines 
      and response to morphine treatment in cancer patients.
PG  - 4561-8
AB  - Cytokine signaling is involved in pain and opioid-receptor signaling. In this 
      prospective study, we studied the plasma cytokine levels in order to identify 
      candidate biomarkers for predicting resistance to morphine treatment in a cohort 
      of opioid-treatment-naive cancer patients. We analyzed pain rating and the plasma 
      concentrations of 26 cytokines at baseline and after morphine treatment using a 
      multiplex immunoassay system for the following cytokines: eotaxin, colony 
      stimulating factor, granulocyte (G-CSF), colony stimulating factor 
      granulocyte-macrophage (GM-CSF), interferon alpha2 (IFN-alpha2), IFN-gamma, interleukin 1alpha 
      (IL-1alpha), IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40), 
      IL-12 (p70), IL-13, IL-15, IL-17, IP-10, monocyte chemotactic protein 1 (MCP-1), 
      macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, tumor necrosis factor-alpha 
      (TNF-alpha) and TNF-beta. No correlation was observed between the clinical 
      characteristics and the numerical rating scale for pain at baseline or among 
      patients who developed resistance to morphine treatment. Interestingly, the 
      plasma concentration of MIP-1alpha significantly decreased during morphine treatment 
      (day 8 vs. baseline, p=0.03). Regarding the baseline plasma cytokine 
      concentrations, none of the cytokine levels were correlated with the numerical 
      rating scale for pain at baseline; however, the baseline plasma concentrations of 
      eotaxin, IL-8, IL-12 (p40), IL-12 (p70), MIP-1alpha and MIP-1beta were significantly 
      lower in patients who required a high dose of morphine or who developed 
      resistance to morphine treatment. In conclusion, this is the first report 
      revealing that the plasma concentrations of several cytokines were significantly 
      modulated during treatment and were correlated with treatment outcome of 
      morphine. Our results suggest that plasma cytokine levels may be promising 
      biomarkers for morphine treatment and that they warrant further study.
FAU - Makimura, Chihiro
AU  - Makimura C
AD  - Department of Medical Oncology, Kinki University Faculty of Medicine, 
      Osaka-Sayama, Osaka, Japan.
FAU - Arao, Tokuzo
AU  - Arao T
FAU - Matsuoka, Hiromichi
AU  - Matsuoka H
FAU - Takeda, Masayuki
AU  - Takeda M
FAU - Kiyota, Hidemi
AU  - Kiyota H
FAU - Tsurutani, Junji
AU  - Tsurutani J
FAU - Fujita, Yoshihiko
AU  - Fujita Y
FAU - Matsumoto, Kazuko
AU  - Matsumoto K
FAU - Kimura, Hideharu
AU  - Kimura H
FAU - Otsuka, Masatomo
AU  - Otsuka M
FAU - Koyama, Atsuko
AU  - Koyama A
FAU - Imamura, Chiyo K
AU  - Imamura CK
FAU - Yamanaka, Takeharu
AU  - Yamanaka T
FAU - Tanaka, Kyoko
AU  - Tanaka K
FAU - Nishio, Kazuto
AU  - Nishio K
FAU - Nakagawa, Kazuhiko
AU  - Nakagawa K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Chemokine CCL3)
RN  - 0 (Cytokines)
RN  - 187348-17-0 (Interleukin-12)
RN  - 76I7G6D29C (Morphine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/metabolism
MH  - Chemokine CCL3/blood
MH  - Cytokines/*blood
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Interleukin-12/blood
MH  - Male
MH  - Middle Aged
MH  - Morphine/*therapeutic use
MH  - Neoplasms/blood/*drug therapy
MH  - Prospective Studies
EDAT- 2011/12/27 06:00
MHDA- 2012/02/23 06:00
CRDT- 2011/12/27 06:00
PHST- 2011/12/27 06:00 [entrez]
PHST- 2011/12/27 06:00 [pubmed]
PHST- 2012/02/23 06:00 [medline]
AID - 31/12/4561 [pii]
PST - ppublish
SO  - Anticancer Res. 2011 Dec;31(12):4561-8.